What genetic testing is recommended, and how would results change care?

Genetic testing for Fuchs dystrophy is not standard clinical care, and results would rarely change management today.

No professional guideline currently recommends routine genetic testing for Fuchs endothelial corneal dystrophy. The reason is straightforward: the most common genetic finding, the CTG trinucleotide repeat expansion in the TCF4 gene, is present in about 70-80% of Caucasian cases [1], but knowing that does not alter the treatment path. There is no gene therapy, no targeted drug that depends on the TCF4 genotype, and no preventive strategy proven to slow progression in a carrier. The clinical decision to operate or wait is made on corneal thickness, guttae density, and visual symptoms, not on a genetic report [2].

The evidence that exists is almost entirely about disease biology, not about clinical utility. A 2025 review synthesizing 31 omics studies confirmed that TCF4-related RNA mis-splicing and extracellular matrix dysregulation are central to the disease [1], but none of those studies tested whether genetic information improved patient outcomes. The early-onset COL8A2 mutation (p.L450W) is a rare exception: finding it in a young person with corneal changes might justify closer monitoring, because the mutation causes aggressive disease before age 40 [3]. Even then, the management is the same: watch, then operate when the cornea swells.

The evidence base is thin on the question that matters to a patient: would a genetic test change what is done for you or your child? The answer from the retrieved studies is no. The one scenario where testing might matter is in a family with multiple affected members, where identifying the specific mutation could clarify inheritance risk for other relatives. But that is a reproductive counseling question, not a treatment question.

My call: genetic testing for Fuchs dystrophy is not recommended in routine care because the results do not change management. Confidence: high.